KTTA
Pasithea Therapeutics Corp.NASDAQHealthcare$0.77+3.48%ClosedMarket Cap: $5.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
2741.00
DCF Value
$7,845.11
FCF Yield
-26118.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-147.9%
ROA
-33.9%
ROIC
-37.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-20.85B | $-20.42B | $1.41 | — |
| FY 2025 | $0.00 | NaN% | $-20.86B | $-20.43B | $-2.91 | — |
| Q3 2025 | $0.00 | -Infinity% | $-3.1M | $-3.0M | $-0.41 | — |
| Q2 2025 | $0.00 | NaN% | $-3.8M | $-3.7M | $-0.66 | — |
| Q1 2025 | $0.00 | NaN% | $-3.7M | $-3.6M | $-3.25 | — |
| Q4 2024 | $0.00 | -Infinity% | $-3.3M | $-3.2M | $-2.90 | — |
| FY 2024 | $0.00 | NaN% | $-14.2M | $-13.9M | $-12.69 | — |
| Q3 2024 | $0.00 | NaN% | $-3.0M | $-3.0M | $-2.87 | — |
| Q2 2024 | $0.00 | NaN% | $-3.9M | $-3.9M | $-3.71 | — |
| Q1 2024 | $0.00 | NaN% | $-4.0M | $-3.9M | $-3.70 | — |
| Q4 2023 | $0.00 | -Infinity% | $-5.1M | $-5.0M | $-4.85 | — |
| FY 2023 | $0.00 | NaN% | $-16.0M | $-16.0M | $-13.01 | — |